Biochimica et Biophysica Acta-Reviews on Cancer

Biochimica et Biophysica Acta (BBA) - Reviews on Cancer is a hybrid open access review journal published in Amsterdam by Elsevier, begun in 1974 as a review section of the Biochimica et Biophysica Acta family and today the only dedicated review title among the ten BBA journals, with a 2025 Journal Impact Factor of 11.2 and Q1 standing in biochemistry and molecular biology, biophysics and oncology（Biochimica et Biophysica Acta - Reviews on Cancer）简称（BBA Reviews on Cancer），由（Elsevier）在阿姆斯特丹出版，1974 年作为（Biochimica et Biophysica Acta）家族的评论板块创刊，如今是该家族十种期刊中唯一的专题综述刊，2025 年影响因子为 11.2，在生化与分子生物学、生物物理与肿瘤学三类均列 Q1 区。

Scope

• Its declared scope is the whole field of the biology and biochemistry of cancer, presented as critical invited reviews of new developments investigated at the molecular level其既定范围是癌症生物学与生物化学的整个领域，以关于分子水平癌症研究新进展的批判性特邀综述形式呈现。
• It emphasizes oncogenes and tumour suppressor genes together with growth-related control of cell cycle signalling它着重癌基因与抑癌基因，以及与生长相关的细胞周期信号控制。
• Carcinogenesis mechanisms and cell transformation form a further core theme of the journal癌变机制与细胞转化是该刊另一核心主题。
• Immunologic control mechanisms of tumours and the genetics of human and mammalian cancer are both within its remit肿瘤的免疫控制机制与人类及哺乳动物癌症的遗传学都在其收录范围之内。
• The scope also names control of cell proliferation, the genetic and molecular control of organismic development, and rational anti-tumour drug design其范围还点明细胞增殖调控、生物体发育的遗传与分子调控以及合理的抗肿瘤药物设计。
• It publishes mini-reviews and full reviews, older issues also carried opinion pieces and meeting reports, and every review is refereed in the same way as a regular research paper with no more than five co-authors该刊刊发迷你综述与完整综述，早期还刊载观点文章与会议纪要，所有综述都按普通研究论文的同等标准评审，合著者不超过五人。

History

• The parent Biochimica et Biophysica Acta was launched in 1947 as the first international journal devoted jointly to biochemistry and biophysics and as the first Elsevier title to carry dedicated subject sections and special issues母刊（Biochimica et Biophysica Acta）于 1947 年创刊，是首份同时面向生物化学与生物物理的国际期刊，也是（Elsevier）首个设立专门学科板块与专辑特刊的刊物。^[1]
• Reviews on Cancer commenced in 1974, alongside the review sections on biomembranes from 1972 and on bioenergetics from 1973, and it is the only one of those three review sections that still survives as a separate title癌症评论板块创刊于 1974 年，与 1972 年的生物膜评论板块、1973 年的生物能学评论板块同期设立，三者中只有它作为独立刊名延续至今。
• Its articles keep the continuous volume numbering of the parent journal, running from volume 355 in 1974 through volumes 1878, 1879 and 1880 in 2023, 2024 and 2025其文章沿用母刊的连续卷号，从 1974 年的第 355 卷一直编到 2023、2024、2025 年的第 1878、1879、1880 卷。
• Its cadence shifted several times, four issues to a volume from 1974 to 1984, three issues to a volume in the later 1980s and 1990s, two volumes of two issues each year from 2001 to 2021, and a single annual volume of six issues from 2022其刊期多次调整，1974 至 1984 年每卷四期，1980 年代后期至 1990 年代每卷三期，2001 至 2021 年每年出两卷、每卷两期，2022 年起改为每年一卷六期。
• The Journal Impact Factor moved from 10.68 for 2021 and 11.414 for 2022, fell to 8.3 for 2024, then recovered to 11.2 for 2025, and the reported CiteScore is 14.1其影响因子 2021 年为 10.68、2022 年为 11.414，2024 年降到 8.3，2025 年回升至 11.2，（CiteScore）报为 14.1。
• A companion online service called BBA Reviews on Cancer Online was edited by Nic C. Jones of the Paterson Institute for Cancer Research in Manchester and David M. Livingston of the Dana-Farber Cancer Institute in Boston, and Elsevier has lodged the whole run from 1974 in the CLOCKSS and Portico archives其配套在线服务（BBA Reviews on Cancer Online）由曼彻斯特（Paterson Institute for Cancer Research）的（Nic C. Jones）与波士顿（Dana-Farber Cancer Institute）的（David M. Livingston）主持，爱思唯尔已把 1974 年以来的全部卷期送入（CLOCKSS）与（Portico）存档。

Editors

• Elsevier presents the ten BBA titles as run by scientists for scientists, each led by executive editors under a family editor-in-chief, currently Daniel Otzen, professor of nanobiotechnology at the Interdisciplinary Nanoscience Center of Aarhus University（Elsevier）称（BBA）十刊由科学家为主持、每刊设执行编辑并受家族总编辑指导，现任家族总编辑是（Aarhus University）跨学科纳米科学中心的纳米生物技术教授（Daniel Otzen）。
• Marina Holz and Erwei Song are listed as executive editors of this title, and the official profile at Sun Yat-sen University records Song as co-executive editor of the journal（Marina Holz）与（Erwei Song）列为该刊执行编辑，中山大学官方网页亦记载（Erwei Song）担任该刊共同执行编辑。
• Chinese indexing records and a May 2025 editorial report give Kornelia Polyak, professor of medicine at the Dana-Farber Cancer Institute and Harvard Medical School known for work on breast tumour heterogeneity and evolution, as editor-in-chief, subject to the current Elsevier listing中文检索记录与 2025 年 5 月的报道把该刊主编记为（Kornelia Polyak），她是（Dana-Farber Cancer Institute）与（Harvard Medical School）的医学教授，以乳腺肿瘤异质性与演化研究著称，具体任命仍以（Elsevier）官方页面为准。^[2]
• Executive editors draw on the journals' networks and Elsevier reviewer platforms to choose referees, and the family editor-in-chief describes the shared standard of the ten titles as quality, collaboration and transparent peer review执行编辑依托各刊学术网络与（Elsevier）的审稿人平台遴选评审人，家族总编辑把十刊共同遵循的标准概括为质量、协作与透明的同行评审。
• Manuscripts are registered and submitted online, the editorial mailbox is bbacan at the Elsevier domain, and the online publication interval reported under the Elsevier banner averages about 5.8 weeks稿件须注册后在线提交，编辑部邮箱为（bbacan@elsevier.com），按爱思唯尔自报口径，从投稿到在线发表平均约 5.8 周。
• The journal takes part in the biennial BBA Rising Stars awards, whose recipients are identified by the executive editors of the participating titles, and the special issue format that the BBA family pioneered remains a regular part of its content该刊参与两年一度的（BBA）新星评选，获奖人由参与评选的各刊执行编辑推举，（BBA）家族率先推行的专辑特刊也仍是其常规内容。